Derek Archila
Stock Analyst at Wells Fargo
(4.00)
# 647
Out of 4,667 analysts
151
Total ratings
42.7%
Success rate
14.46%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Initiates: Overweight | $43 | $22.50 | +91.11% | 1 | Nov 19, 2024 | |
| CABA Cabaletta Bio | Maintains: Overweight | $20 → $12 | $2.26 | +430.97% | 7 | Nov 15, 2024 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $44 → $24 | $4.12 | +482.52% | 1 | Nov 15, 2024 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $20 → $11 | $7.49 | +46.86% | 10 | Nov 14, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $43 → $30 | $27.49 | +9.13% | 10 | Nov 6, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $547 → $639 | $591.82 | +7.97% | 9 | Nov 1, 2024 | |
| ZYME Zymeworks | Downgrades: Equal-Weight | $12 | $14.55 | -17.53% | 4 | Nov 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $153 → $151 | $94.81 | +59.27% | 8 | Oct 31, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $62 → $68 | $71.05 | -4.29% | 5 | Oct 30, 2024 | |
| EXEL Exelixis | Maintains: Overweight | $32 → $36 | $34.65 | +3.90% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $4.43 | +238.60% | 4 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.99 | +468.56% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $124.38 | +132.35% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.72 | +539.53% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $26.40 | +40.15% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $38 | $44.05 | -13.73% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $8.36 | +103.35% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $29 → $9 | $3.13 | +187.54% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $5.16 | +93.80% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $8 | $4.05 | +97.53% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $60 | $22.69 | +164.43% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $59.36 | -12.40% | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $56 | $20.31 | +175.73% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $22.64 | -11.66% | 4 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $48 | $26.17 | +83.42% | 8 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.41 | +729.88% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $24 | $4.32 | +455.56% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.74 | +556.93% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.31 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $25.64 | +652.73% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $113.16 | -63.77% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $8 | $0.49 | +1,518.12% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $12 | $0.51 | +2,262.20% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.90 | +491.84% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.12 | +4,364.29% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $11.45 | +345.41% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $27.15 | +224.13% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $17.03 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.03 | - | 2 | Aug 3, 2017 |
Septerna
Nov 19, 2024
Initiates: Overweight
Price Target: $43
Current: $22.50
Upside: +91.11%
Cabaletta Bio
Nov 15, 2024
Maintains: Overweight
Price Target: $20 → $12
Current: $2.26
Upside: +430.97%
Kyverna Therapeutics
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $4.12
Upside: +482.52%
Kezar Life Sciences
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $20 → $11
Current: $7.49
Upside: +46.86%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $27.49
Upside: +9.13%
argenx SE
Nov 1, 2024
Maintains: Overweight
Price Target: $547 → $639
Current: $591.82
Upside: +7.97%
Zymeworks
Nov 1, 2024
Downgrades: Equal-Weight
Price Target: $12
Current: $14.55
Upside: -17.53%
Blueprint Medicines
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $94.81
Upside: +59.27%
Incyte
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $62 → $68
Current: $71.05
Upside: -4.29%
Exelixis
Oct 30, 2024
Maintains: Overweight
Price Target: $32 → $36
Current: $34.65
Upside: +3.90%
Oct 16, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $4.43
Upside: +238.60%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $2.99
Upside: +468.56%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $124.38
Upside: +132.35%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.72
Upside: +539.53%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $26.40
Upside: +40.15%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $30 → $38
Current: $44.05
Upside: -13.73%
Aug 12, 2024
Maintains: Overweight
Price Target: $18 → $17
Current: $8.36
Upside: +103.35%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $29 → $9
Current: $3.13
Upside: +187.54%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $5.16
Upside: +93.80%
May 9, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $4.05
Upside: +97.53%
May 9, 2024
Maintains: Overweight
Price Target: $63 → $60
Current: $22.69
Upside: +164.43%
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $59.36
Upside: -12.40%
Apr 11, 2024
Initiates: Overweight
Price Target: $56
Current: $20.31
Upside: +175.73%
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $22.64
Upside: -11.66%
Sep 27, 2023
Maintains: Overweight
Price Target: $33 → $48
Current: $26.17
Upside: +83.42%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.41
Upside: +729.88%
Mar 11, 2021
Upgrades: Buy
Price Target: $4 → $24
Current: $4.32
Upside: +455.56%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $2.74
Upside: +556.93%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.31
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $25.64
Upside: +652.73%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $113.16
Upside: -63.77%
Mar 31, 2020
Maintains: Hold
Price Target: $24 → $8
Current: $0.49
Upside: +1,518.12%
Mar 17, 2020
Downgrades: Hold
Price Target: $36 → $12
Current: $0.51
Upside: +2,262.20%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.90
Upside: +491.84%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.12
Upside: +4,364.29%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $11.45
Upside: +345.41%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $27.15
Upside: +224.13%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $17.03
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $17.03
Upside: -